Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model.
Phosphorylcholine (PC)-coated stents have shown excellent blood and tissue biocompatibility in porcine coronary arteries. The purpose of this study was to determine the efficacy of local methylprednisolone (MP) delivery using PC-coated stents to inhibit inflammatory response and in-stent neointimal hyperplasia in an overstretched porcine coronary model. BiodivYsio (Biocompatibles, Farnham, Surrey, UK) PC-coated drug delivery (DD) stents and DD stents loaded with a high dose of MP (269 microg) were implanted in the coronary arteries of 20 pigs with a balloon/artery ratio of 1.2 : 1. At five days the peri-strut inflammatory response score and thrombus score of the MP-loaded DD stents were lower than in the control stents. The neointimal hyperplasia of MP-loaded DD stents was significantly reduced (0.80 +/- 0.10 versus 0.48 +/- 0.10 mm(2), p < 0.01). At four-week follow-up, the inflammatory response of MP-loaded stents was lower than the control stents, but without significant difference. The MP-loaded stents showed decreased peri-strut arterial injury and in-stent neointimal hyperplasia (2.42 +/- 0.87 versus 1.62 +/- 0.71 mm(2), p < 0.05). It is concluded that local vascular delivery of a high dose of MP from PC-coated DD stents could effectively decrease inflammatory response and thrombus formation after oversized stent deployment and result in a significant reduction of neointimal hyperplasia.
Huang
Yanming
Y
Department of Cardiology, University Hospitals Gasthuisberg, Leuven, Belgium.
Liu
Xiaoshun
X
Wang
Lan
L
Verbeken
Eric
E
Li
Shengqiao
S
De Scheerder
Ivan
I
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects*; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage* / Q000627:therapeutic use*; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000187:drug effects* / Q000473:pathology / Q000601:surgery*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems / Q000009:adverse effects*; D005260:Female; D006965:Hyperplasia / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D007249:Inflammation / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000627:therapeutic use*; D010767:Phosphorylcholine / Q000008:administration & dosage* / Q000627:therapeutic use*; D015607:Stents / Q000009:adverse effects*; D013552:Swine; D013997:Time Factors; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology / Q000601:surgery*
D000893:Anti-Inflammatory Agents; D020099:Coated Materials, Biocompatible; D010767:Phosphorylcholine; D008775:Methylprednisolone